Embody is the safer choice in mid-2026. While both programs offer compounded semaglutide at competitive prices, SkinnyRx received an FDA Warning Letter (#717989) in February 2026 that raises transparency questions. Embody's clinical support model and clean regulatory record make it the more trustworthy option for patients weighing these two.
Embody and SkinnyRx are among the most heavily marketed GLP-1 telehealth programs in 2026. Both promise affordable access to compounded semaglutide. Both run aggressive digital advertising. And both target the same patient: someone who wants GLP-1 weight loss medication without the brand-name price tag.
But there are meaningful differences beneath the surface — especially since February 2026.
| Feature | Embody | SkinnyRx |
|---|---|---|
| Medication | Compounded injectable semaglutide | Compounded semaglutide (injectable + oral) |
| First Month | $149 | ~$149–$199 (varies) |
| Ongoing | $299/mo | ~$299–$399/mo |
| Formats | Injectable only | Injectable + oral gum/troche |
| Clinical Support | Ongoing clinician access | Intake-focused |
| FDA Warning Letter | None | Yes — #717989 (Feb 2026) |
Embody focuses exclusively on compounded injectable semaglutide. They don't offer tirzepatide, oral formats, or other compounds. This narrower focus means they can concentrate their clinical protocols on a single medication pathway.
SkinnyRx offers a broader product line, including oral semaglutide formulations (gum and troche formats). However, the FDA Warning Letter raises questions about how these products are marketed and whether claims made about them are fully substantiated.
This is where the programs diverge most. Embody emphasizes ongoing clinical support — patients have continued access to their prescribing clinician for dose adjustments, side effect management, and treatment monitoring. The intake process includes a medical history review and clinical screening.
SkinnyRx's model is more intake-focused. The initial medical review facilitates the prescription, but ongoing clinical touchpoints are less prominently featured in their program structure.
For a medication that requires careful dose titration over months (starting at 0.25mg and titrating up to 2.4mg for semaglutide), ongoing clinical oversight matters. Under-titration means suboptimal results; over-titration risks more severe side effects.
Embody publishes clear pricing: $149 for the first month, $299/mo ongoing. What you see is what you pay.
SkinnyRx's pricing has been less consistently transparent. Advertised prices on landing pages don't always match what patients report paying after enrollment. Several patient reports indicate promotional pricing that increases after the first billing cycle. We were unable to verify a single, consistent price across all SkinnyRx marketing materials at the time of this review.
This is the decisive differentiator. Embody has no FDA warning letters, no regulatory actions, and no public compliance concerns as of July 2026.
SkinnyRx received FDA Warning Letter #717989 in February 2026. While an FDA warning letter is not the same as a product recall or a safety ban, it does indicate that the FDA identified concerns serious enough to warrant formal action. For a YMYL (Your Money or Your Life) category like weight loss medication, regulatory trust matters.
For patients choosing between these two specific programs, Embody is the clearer choice. The combination of transparent pricing, ongoing clinical support, a clean regulatory record, and a focused product line makes it a lower-risk option.
If you want the broader oral format options that SkinnyRx offers, consider Wellorithm (compounded oral tablets at $147/mo for semaglutide) or Sesame Care (FDA-approved brand-name oral options) as alternatives that don't carry the same regulatory concerns.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. GLP-1 receptor agonists carry risks including thyroid tumors, pancreatitis, and other serious side effects. Individual results vary. Compounded medications are not FDA-approved and carry additional risks.
Affiliate Disclosure: Compare GLP-1 earns commissions from qualifying purchases through affiliate links on this page. This does not influence our editorial verdicts. All prices shown are verified as of the date listed and are subject to change.